A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma

PURPOSE: Patients with International Metastatic RCC Database Consortium (IMDC) poor risk metastatic renal cell carcinoma (mRCC) rarely respond to first-line tyrosine kinase inhibitors (TKIs) including sunitinib, and carries a very poor prognosis. In recent years, combination therapy involving immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Hyunji, Hong, Joohyun, Kim, Hongsik, Kim, Hye Ryeon, Kwon, Ghee Young, Kang, Kyung A., Park, Sung Yoon, Kim, Chan Kyo, Park, Byung Kwan, Chung, Jae Hoon, Song, Wan, Kang, Minyong, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Park, Se Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095911/
https://www.ncbi.nlm.nih.gov/pubmed/35574412
http://dx.doi.org/10.3389/fonc.2022.874385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095911/
https://www.ncbi.nlm.nih.gov/pubmed/35574412
http://dx.doi.org/10.3389/fonc.2022.874385

Ejemplares similares